Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2025.
Info
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
Externer Link zu ICON plc
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Dublin
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs und Global Patient Insights & Engagement
Orte
Beschäftigte von ICON plc
Updates
-
Focussing on two key elements can help developers to enhance their chances of success in the diverse, evolving oncology landscape. Read this PharmaTimes article and learn how target product profiles and biomarkers for patient screening can help oncology developers to de-risk their clinical development. https://ow.ly/UxMj50UqruS
-
-
ICON recently received a 2024 Scrip award for Best Contract Research Organisation - Full Service Providers. This recognition follows a number of accolades in the second half of 2024, including TIME Magazine’s 2024 list of World’s Best Companies and its 2025 list of World’s Best Companies in Sustainable Growth. Read more about ICON’s recent successes here: https://ow.ly/a4Zj50UuNQ1 #ICONCares #leadership #ClinicalResearch
-
-
Determine drug efficacy sooner with tumour growth rate (TGR) modelling in your study. Learn about TGR modelling's advantages over other conventional biomarker imaging methods in our new whitepaper. https://ow.ly/c01E50TT4UY #medicalimaging #oncology
-
-
ICON has a range of central laboratory solutions to support the specific needs of biotech companies operating in complex and rapidly evolving drug development environments. Find out more: https://ow.ly/iWiY50TJuX5
-
-
Reaching and educating underserved patient populations in a compliant and impactful way is no small feat. In Q1 2024, Underscore Marketing set a new benchmark with an unbranded campaign for patients with a rare lung disease. By leveraging PulsePoint’s Qualified Audience Reach (QAR) metric and collaborating with Symphony Health, the campaign identified and reached patients efficiently and compliantly. Symphony Health stood out, achieving a cumulative QAR score of 2.3 and reaching over 100 qualified patients in just three days—half the time it took other providers. Read our latest case study to find out how: https://ow.ly/sAxN50Usp3F #HealthcareMarketing #DataDriven #PatientCentricCare
-
-
Barry Balfe, ICON Pharma Solutions President, featured in The Irish Times discussing the pivotal role of life sciences in Ireland's economic success and the steps needed to secure the country’s competitive edge. Barry highlights Ireland’s strong foundation in biopharma, medtech, and life sciences R&D, emphasising the importance of public investment in research, adapting to revolutions in AI and biomedical science, and addressing key challenges like infrastructure and clinical trial regulations. Read the full article here: https://ow.ly/aJfH50UtY0F #LifeSciences #R&D #Ireland #Leadership #ICONPharma
-
-
Signal detection, global regulatory compliance, and advanced technologies in pharmacovigilance: just some of the topics covered at 2024 World Drug Safety Congress recently. ICON experts attended and report on the discussions and emerging trends in this blog. Read the article. https://ow.ly/GNJH50UqwKt
-
-
Simplifying clinical supplies management with FlexAdvantage just got easier. The newest enhancements to FlexAdvantage streamline your clinical supply chain with: - Intuitive navigation with seamless access - Shipment acknowledgment reminders - Automated temperature excursion tracking for compliance - End-to-end efficiency to keep your trial on track Learn how FlexAdvantage transforms your clinical supply chain: https://ow.ly/CFW450UuNkI
-
We demystify the systematic literature review (SLR) process by providing an overview of the steps involved in conducting an SLR, when to conduct an SLR, and how SLRs contribute to evidence-based medicine and improve patient outcomes. View the on demand webinar: https://ow.ly/rkSs50UqrqG
-
Verbundene Seiten
Ähnliche Seiten
Finanzierung
ICON plc
Insgesamt 1 Finanzierungsrunde
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
2.000.000.000,00 $